Zurich, Munich – Biognosys, a Swiss next-generation proteomics company, has secured significant funding from a corporate investment fund. The company is using the Series-C financing round to establish business development and service operations in the US and to develop new workflows and products for high-content protein analysis. Biognosys’ new operations will be established in Boston, which is home to one of the largest biopharma clusters in the US.
Biognosys has a strong, reputable international investor base and an excellent scientific and management team led by CEO and co-founder of Biognosys Dr. Oliver Rinner who says: ‘We believe that the ability to decode the proteome is key for a better understanding of life and will help to develop better drugs, crops, diagnostics and biomaterials in the future. Our mission is to enable researchers to effortlessly analyze whole proteomes by providing superior and easy to use analytical technology’.
The new shareholder and the amount invested have not been disclosed.
About Biognosys AG
BIOGNOSYS AG, founded in 2008, is a privately held company located in Zurich, Switzerland. The company is an ETH Zurich spin-off from the lab of Prof. Ruedi Aebersold. Biognosys is a pioneer in the field of proteomics and caters to the Pharma, Biotech, Diagnostics and Agricultural industries. Biognosys provides innovative services and products for protein discovery and quantification using cutting edge and patent-protected technology. The technology is based on mass spectrometry and provides simultaneous quantification for thousands of proteins with unbeatable precision and depth in a single experiment. For further information, please visit www.biognosys.ch.
CatCap and the international M[&]A network Globalscope offer integrated cross-border M[&]A consulting services for medium-sized transactions. CatCap – a partner led corporate finance firm – advises businesses and shareholders to realise their strategic objectives ensuring the highest level of quality. CatCap is based in Hamburg and Munich with 19 employees. Globalscope has 46 members in 39 countries with more than 500 professionals worldwide. For further information about CatCap, please visit www.carlsquare.com.